日本医药市场报告（依处方类型、治疗类别和地区）2025-2033

2024年，日本医药市场规模达822.7亿美元。展望未来， IMARC Group预计到2033年市场规模将达到1,019亿美元，2025-2033年期间的成长率（CAGR）为2.57%。众多的治疗方法和创新疗法以及对药物研发活动不断增加的投资，主要促进了市场的成长。

製药业代表科学、创新和治疗护理的融合，致力于促进全球健康。该行业的核心是负责研究、开发、生产和分销用于预防、控製或治疗多种医疗状况和疾病的药物。从救命的疫苗到日常止痛药，药品在提高生活品质和延长寿命方面发挥着不可或缺的作用。药物开发过程是一个复杂而严格的过程，需要进行大量的研究、临床试验和监管部门的批准，以确保药物的疗效和对病人的安全。除了有形的药物之外，製药业的价值还在于其对新治疗前沿、突破性治疗方法和可能重新定义医学范式的创新的不懈追求。随着健康挑战的不断演变，该行业的重要性（以其改善人类健康的承诺为基础）仍然至关重要。

日本医药市场趋势：

生物製药和精准医疗的投资不断增加

生物製药和精准医疗投资的不断增长正在迅速改变日本製药业的动态。生物製药，例如生物製剂和生物仿製药，由于在治疗癌症或自体免疫疾病等慢性疾病方面的独创性而越来越受到青睐。随着基因组学和个人化医疗的进步，治疗重点正转向针对个人基因特征的客製化治疗。因此，日本主要製药商正在与海外公司和研究中心建立合资企业来培育这项技术。透过对个人化治疗的加强关注，为以前难以解决的疾病提供有针对性的解决方案，进一步扩大了医药市场的范围。

人口老化和医疗保健需求成长

人口快速老化是推动医药市场成长的关键因素。这种人口结构的变化增加了与年龄相关的疾病和心血管疾病、糖尿病和阿兹海默症等慢性疾病的药物的整体需求。此外，随着人们的注意力转向管理慢性病和改善老年人的生活质量，随着医疗保健系统的改善，对有效治疗和药物的需求也在增长。此外，药厂正在​​加大老年药物的研发力度，开发专门针对老年护理的综合药物配方。这一人口趋势吸引了国内外公司的大量投资，为日本医药市场的份额做出了贡献。

药物开发和製造技术的不断进步

人工智慧 (AI)、机器学习 (ML) 和流程自动化等尖端技术的持续创新，特别是它们融入临床前研究和药物製造中，正在支持市场的成长。临床试验和药物安全监测中的数据驱动方法正在帮助製药公司更快地将新疗法推向市场。穿戴式装置和数位健康工具（包括远距医疗）也在促进更好的药物依从性和更个人化的治疗计画。此外，生物加工方面的创新和机器人技术在药品生产中的应用正在提高效率，而先进的分析技术则支援在整个药物开发生命週期中做出更好的决策。

日本医药市场细分：

处方类型洞察：

• 处方药
  • 品牌
  • 泛型
• 非处方药

治疗类别洞察：

• 抗过敏药
• 血液和造血器官
• 心血管系统
• 皮肤
• 泌尿生殖系统
• 呼吸系统
• 感觉器官
• 其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

日本医药市场新闻：

• 2024 年 10 月 1 日，Nxera Pharma Co., Ltd. 与 Shionogi & Co., Ltd. 就 QUVIVIQ(TM)（daridorexant 25 和 50 毫克）在日本的分销和销售达成合作协议。 QUVIVIQ 是由 Idorsia Pharmaceuticals Ltd 发现的一种新型双食慾素受体拮抗剂，已获得日本厚生劳动省（「MHLW」）批准用于治疗成年失眠患者。

本报告回答的关键问题：

• 日本医药市场迄今表现如何？未来几年将如何表现？
• COVID-19 对日本医药市场有何影响？
• 日本药品市场如何依处方类型划分？
• 日本医药市场如何按治疗类别划分？
• 日本医药市场的价值链分为哪些阶段？
• 日本製药业的主要驱动因素和挑战是什么？
• 日本医药市场的结构是怎么样的？主要参与者是谁？
• 日本医药市场的竞争程度如何？

本报告回答的关键问题：

• 日本医药市场迄今表现如何？未来几年将如何表现？
• COVID-19 对日本医药市场有何影响？
• 日本药品市场如何依处方类型划分？
• 日本医药市场如何按治疗类别划分？
• 日本医药市场的价值链分为哪些阶段？
• 日本製药业的主要驱动因素和挑战是什么？
• 日本医药市场的结构是怎么样的？主要参与者是谁？
• 日本医药市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 次要来源
• 市场评估
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章：执行摘要

第四章：日本医药市场-简介

• 概述
• 市场动态
• 产业趋势
• 竞争情报

第五章：日本医药市场格局

• 历史与当前市场趋势（2019-2024）
• 市场预测（2025-2033）

第六章：日本医药市场-细分：依处方类型

• 处方药
  • 概述
  • 市场区隔
    • 品牌
    • 泛型
• 非处方药
  • 概述

第七章：日本医药市场-细分：依治疗类别

• 抗过敏药
  • 概述
• 血液和造血器官
  • 概述
• 心血管系统
  • 概述
• 皮肤
  • 概述
• 泌尿生殖系统
  • 概述
• 呼吸系统
  • 概述
• 感觉器官
  • 概述
• 其他的

第八章：日本医药市场-竞争格局

• 概述
• 市场结构
• 市场参与者定位
• 最佳获胜策略
• 竞争仪錶板
• 公司评估象限

第九章：关键参与者简介

• Company A
• Business Overview
• Product Portfolio
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company B
• Business Overview
• Product Portfolio
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company C
• Business Overview
• Product Portfolio
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company D
• Business Overview
• Product Portfolio
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company E
• Business Overview
• Product Portfolio
• Business Strategies
• SWOT Analysis
• Major News and Events

第十章：日本医药市场-产业分析

• 驱动因素、限制因素和机会
  • 概述
  • 驱动程式
  • 限制
  • 机会
• 波特五力分析
  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁
• 价值链分析

第 11 章：附录

Japan pharmaceutical market size reached USD 82.27 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 101.90 Billion by 2033, exhibiting a growth rate (CAGR) of 2.57% during 2025-2033. Numerous treatments and innovative therapies and the increasing investments in the R&D activities for developing medicines, are primarily augmenting the market growth.

The pharmaceutical industry represents a confluence of science, innovation, and therapeutic care, dedicated to advancing global health. At its core, this sector is responsible for the research, development, production, and distribution of medications designed to prevent, manage, or cure a plethora of medical conditions and diseases. Spanning from life-saving vaccines to everyday pain relievers, pharmaceuticals play an integral role in enhancing the quality of life and increasing life expectancy. The journey of drug development is a complex and rigorous process, necessitating extensive research, clinical trials, and regulatory approvals to ensure both efficacy and safety for patients. Beyond the tangible medications, the pharmaceutical industry's value also lies in its relentless pursuit of new therapeutic frontiers, breakthrough treatments, and innovations that have the potential to redefine medical paradigms. As health challenges continue to evolve, the importance of this industry, underpinned by its commitment to bettering human health, remains paramount.

Japan Pharmaceutical Market Trends:

Growing investments in biopharmaceuticals and precision medicine

Growing investments in biopharmaceuticals and precision medicines is rapidly transforming the dynamics of the pharmaceutical industry in Japan. Biopharmaceuticals, such as biologics, and biosimilars are gaining more preference due to originality in treatment of chronic diseases, such as cancer or autoimmune diseases. With advancements in genomics and personalized medicine, the focus is shifting towards treatments tailored to individual genetic profiles. As a result, major Japanese drug manufacturers are engaging in joint ventures involving overseas companies and research centers to foster this technology. An enhanced focus on individualized treatments is further extending the range of the pharmaceutical market by offering targeted solutions to previously hard-to-solve diseases.

Aging Population and Rising Healthcare Demand

The rapidly aging population is a key factor propelling growth in the pharmaceutical market. This demographic shift is increasing the overall demand for medications targeting age-related diseases and chronic conditions such as cardiovascular diseases, diabetes, and Alzheimer's. Also, with shifting focus to managing chronic illnesses and improving the quality of life for senior citizens, the demand for effective treatments and medications is growing with the improving healthcare system. Furthermore, pharmaceutical companies are expanding their R&D efforts in geriatric medicines, developing comprehensive drug formulations specifically designed for elderly care. This demographic trend is attracting heavy investments from both local and international firms, contributing to the Japan pharmaceutical market share.

Continual technological advancements in drug development and manufacturing

Ongoing innovations in cutting-edge advancements, such as artificial intelligence (AI), machine learning (ML), and process automation, particularly as they are integrated into both preclinical research and drug manufacturing, are supporting the growth of the market. Data-driven methods in clinical trials and drug safety monitoring are helping pharmaceutical companies bring new therapies to market faster. Wearable devices and digital health tools, including telemedicine are also fostering better drug adherence and more personalized treatment plans. Additionally, innovations in bioprocessing and the use of robotics in pharmaceutical production are improving efficiency, while advanced analytics support better decision-making throughout the drug development lifecycle.

Japan Pharmaceutical Market Segmentation:

Prescription Type Insights:

• Prescription Drugs
  • Branded
  • Generics
• OTC Drugs

Therapeutic Category Insights:

• Antiallergics
• Blood and Blood Forming Organs
• Cardiovascular System
• Dermatological
• Genito Urinary System
• Respiratory System
• Sensory Organs
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Japan Pharmaceutical Market News:

• On 1st October 2024, Nxera Pharma Co., Ltd. formed a partnership agreement with Shionogi & Co., Ltd. regarding the distribution and sales for QUVIVIQ(TM) (daridorexant 25 and 50 mg) in Japan. QUVIVIQ is a novel dual orexin receptor antagonist, discovered by Idorsia Pharmaceuticals Ltd, that was approved by the ministry of health, labour, and welfare of Japan ("MHLW") for the treatment of adult patients with insomnia.

Key Questions Answered in This Report:

• How has the Japan pharmaceutical market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan pharmaceutical market?
• What is the breakup of the Japan pharmaceutical market on the basis of prescription type?
• What is the breakup of the Japan pharmaceutical market on the basis of therapeutic category?
• What are the various stages in the value chain of the Japan pharmaceutical market?
• What are the key driving factors and challenges in the Japan pharmaceutical?
• What is the structure of the Japan pharmaceutical market and who are the key players?
• What is the degree of competition in the Japan pharmaceutical market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmaceutical Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Pharmaceutical Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Pharmaceutical Market - Breakup by Prescription Type

• 6.1 Prescription Drugs
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Segmentation
    • 6.1.3.1 Branded
    • 6.1.3.2 Generics
  • 6.1.4 Market Forecast (2025-2033)
• 6.2 OTC Drugs
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)

7 Japan Pharmaceutical Market - Breakup by Therapeutic Category

• 7.1 Antiallergics
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Blood and Blood Forming Organs
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Cardiovascular System
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)
• 7.4 Dermatological
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2019-2024)
  • 7.4.3 Market Forecast (2025-2033)
• 7.5 Genito Urinary System
  • 7.5.1 Overview
  • 7.5.2 Historical and Current Market Trends (2019-2024)
  • 7.5.3 Market Forecast (2025-2033)
• 7.6 Respiratory System
  • 7.6.1 Overview
  • 7.6.2 Historical and Current Market Trends (2019-2024)
  • 7.6.3 Market Forecast (2025-2033)
• 7.7 Sensory Organs
  • 7.7.1 Overview
  • 7.7.2 Historical and Current Market Trends (2019-2024)
  • 7.7.3 Market Forecast (2025-2033)
• 7.8 Others
  • 7.8.1 Historical and Current Market Trends (2019-2024)
  • 7.8.2 Market Forecast (2025-2033)

8 Japan Pharmaceutical Market - Competitive Landscape

• 8.1 Overview
• 8.2 Market Structure
• 8.3 Market Player Positioning
• 8.4 Top Winning Strategies
• 8.5 Competitive Dashboard
• 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

• 9.1 Company A
  • 9.1.1 Business Overview
  • 9.1.2 Product Portfolio
  • 9.1.3 Business Strategies
  • 9.1.4 SWOT Analysis
  • 9.1.5 Major News and Events
• 9.2 Company B
  • 9.2.1 Business Overview
  • 9.2.2 Product Portfolio
  • 9.2.3 Business Strategies
  • 9.2.4 SWOT Analysis
  • 9.2.5 Major News and Events
• 9.3 Company C
  • 9.3.1 Business Overview
  • 9.3.2 Product Portfolio
  • 9.3.3 Business Strategies
  • 9.3.4 SWOT Analysis
  • 9.3.5 Major News and Events
• 9.4 Company D
  • 9.4.1 Business Overview
  • 9.4.2 Product Portfolio
  • 9.4.3 Business Strategies
  • 9.4.4 SWOT Analysis
  • 9.4.5 Major News and Events
• 9.5 Company E
  • 9.5.1 Business Overview
  • 9.5.2 Product Portfolio
  • 9.5.3 Business Strategies
  • 9.5.4 SWOT Analysis
  • 9.5.5 Major News and Events

10 Japan Pharmaceutical Market - Industry Analysis

• 10.1 Drivers, Restraints and Opportunities
  • 10.1.1 Overview
  • 10.1.2 Drivers
  • 10.1.3 Restraints
  • 10.1.4 Opportunities
• 10.2 Porters Five Forces Analysis
  • 10.2.1 Overview
  • 10.2.2 Bargaining Power of Buyers
  • 10.2.3 Bargaining Power of Suppliers
  • 10.2.4 Degree of Competition
  • 10.2.5 Threat of New Entrants
  • 10.2.6 Threat of Substitutes
• 10.3 Value Chain Analysis

11 Appendix